SCHEMBL8088282

SCHEMBL8088282

Cc1ccc(Nc2cc(N(C)C)nc(CCCCc3ccccc3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.50
LMNA P02545 5/20 0.50
KDM4E B2RXH2 4/20 0.50
HTT P42858 3/20 0.50
NPSR1 Q6W5P4 3/20 0.50
USP2 O75604 1/20 0.50
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TP53 P04637 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
POLB P06746 1/20 0.42
GBA1 P04062 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
GPR55 Q9Y2T6 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
TGM2 P21980 1/20 0.41
PLA2G1B P04054 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40
ABCG2 Q9UNQ0 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8098432 0.84 MAPT (0.44) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL3244336 0.84 MAPT (0.57) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL8263174 0.83 MAPT (0.47) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL3233135 0.81 MAPT (0.59) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL3242774 0.80 MAPT (0.49) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL8098487 0.80 METAP2 (0.42) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL8253278 0.79 MAPT (0.74) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL3262414 0.74 MAPT (0.50) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL3244319 0.74 TGM2 (0.68) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL2411151 0.73 TAAR1 (0.58) MAPTLMNAKDM4EHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220775-B2 Compound useful for the treatment of neuropathic pain H. LUNDBECK A/S (DK) 2007-05-22 US disclosed
US-7220775-B2 Compound useful for the treatment of neuropathic pain H. LUNDBECK A/S (DK) 2007-05-22 US disclosed
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2004-05-13 US disclosed
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain GALR3, GALR2, GALR1 MAPT 3177/4885LMNA 2883/4885KDM4E 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.